Last quarter (Q4 2022), Sartorius Stedim Biotech's total revenue was $890.00M, an increase of 14.37% from the same quarter last year. In Q4, Sartorius Stedim Biotech's net income was $186.70M. See Sartorius Stedim Biotech’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Dec 23	Dec 22	Dec 21	Dec 20	Dec 19
Total Revenue	$ 3.49B	$ 2.78B	$ 3.49B	$ 2.89B	$ 1.91B	$ 1.44B
Cost of Revenue	$ 1.66B	$ ―	$ 1.66B	$ 1.33B	$ 906.76M	$ 692.28M
Gross Profit	$ 1.83B	$ ―	$ 1.83B	$ 1.55B	$ 1.00B	$ 748.29M
Operating Expense	$ 751.60M	$ ―	$ 751.70M	$ 670.00M	$ 499.88M	$ 399.64M
Operating Income	$ 1.08B	$ ―	$ 1.08B	$ 883.00M	$ 503.45M	$ 348.65M
Net Non Operating Interest Income Expense	$ -9.40M	$ ―	$ -9.40M	$ -6.70M	$ -12.10M	$ -15.96M
Other Income Expense	$ ―	$ ―	$ ―	$ ―	$ ―	$ ―
Pretax Income	$ 1.13B	$ ―	$ 1.13B	$ 646.70M	$ 460.69M	$ 317.42M
Tax Provision	$ 250.60M	$ ―	$ 250.50M	$ 232.40M	$ 122.09M	$ 81.38M
Earnings From Equity Interest Net Of Tax	$ ―	$ ―	$ ―	$ ―	$ ―	$ ―
Net Income Common Stockholders	$ 876.10M	$ ―	$ 876.10M	$ 414.40M	$ 335.93M	$ 234.50M
Basic EPS	$ ―	$ ―	$ ―	$ ―	$ ―	$ ―
Diluted EPS	$ ―	$ ―	$ ―	$ ―	$ ―	$ ―
Basic Average Shares	$ ―	$ ―	$ ―	$ ―	$ ―	$ ―
Diluted Average Shares	$ ―	$ ―	$ ―	$ ―	$ ―	$ ―
Dividend Per Share	$ ―	$ ―	$ ―	$ ―	$ ―	$ ―
Total Operating Income As Reported	$ ―	$ ―	$ ―	$ ―	$ ―	$ ―
Reported Normalized Basic E P S	$ ―	$ ―	$ ―	$ ―	$ ―	$ ―
Reported Normalized Diluted E P S	$ ―	$ ―	$ ―	$ ―	$ ―	$ ―
Rent Expense Supplemental	$ ―	$ ―	$ ―	$ ―	$ ―	$ ―
Total Expenses	$ 2.41B	$ ―	$ 2.41B	$ 2.00B	$ 1.41B	$ 1.09B
Net Income From Continuing And Discontinued Operation	$ 876.10M	$ ―	$ 876.10M	$ 414.40M	$ 335.93M	$ 234.50M
Normalized Income	$ 876.10M	$ ―	$ 799.62M	$ 567.28M	$ 359.14M	$ 245.87M
Interest Expense	$ 18.60M	$ ―	$ 18.60M	$ 10.40M	$ 6.82M	$ 4.61M
EBIT	$ 1.15B	$ ―	$ 1.15B	$ 657.10M	$ 467.51M	$ 322.03M
EBITDA	$ 1.33B	$ 755.70M	$ 1.33B	$ 798.70M	$ 569.20M	$ 395.40M

Currency in USD

Sartorius Stedim Biotech Earnings and Revenue History

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing